According to the latest report published by Credence Research, Inc. “Actinic Keratosis Market (Liquid Nitrogen Cryotherapy, Surgical Therapy, 5-aminolevulinic acid (ALA), Methyl Aminolevulinate (MAL), 5-fluorouracil, Imiquimod, Ingenol Mebutate, Diclofenac Sodium, Chemical Peels and Others) – Growth, Future Prospects and Competitive Analysis, 2016-2022,” the actinic keratosis market was valued at USD 6,561.8 Mn in 2015 and is expected to reach USD 8,909.7 Mn by 2022, with the market progressing at a CAGR 4.35%from 2016-2022.
Actinic keratosis (AK) is characterized by skin papules, macules or plaques resulting from prolonged exposure to harmful UV exposure and can result in squamous cell carcinoma. Risk of developing actinic keratosis increases with advancing age and is particularly higher in men as against women. About 5-20% of patients with actinic keratosis lesions develop malignant and potentially fatal squamous cell carcinomas.
Among the various treatment methods available, destructive therapies such as liquid nitrogen cryotherapy and surgical therapy constitute the gold standard for AK treatment. In 2015, cryotherapy was the most commonly sought treatment by clinicians. However, better clinical results of photodynamic therapy and growing preference for treatments based on drug-device combination have urged both caregivers and patients to opt for novel treatment methods that offer both advanced efficacy, aesthetic benefits and reduced risk of future malignancies. Topical treatment is a prolonged treatment and comparatively more effective than other treatments but patient compliance is the key issue that hinders the growth of this segment. Photodynamic therapy is the fastest growing treatment throughout the forecast period due to rising demand for non-invasive surgeries, and less treatment sessions are the key factors expected to assist this market.
North America is the largest market for actinic keratosis treatment due to growing prevalence of AK, better public awareness about occurrence of AK and associated risk of squamous cell carcinoma. According to American Academy of Dermatology (AAD), approximately 60% of the Americans aged 40 year or above, Actinic Keratosis is predisposed to develop having at least 1 AK lesion. Actinic keratosis is precursors of squamous cell cancer. U.S. held the largest share in the actinic keratosis market in 2015 owing to current prevalence of actinic keratosis in the region. Asia Pacific is the fastest growing market for AK treatments. Australia has the highest prevalence of actinic keratosis ranging between 40% to 60% in adult population. Growing awareness in the region and rapid development in healthcare infrastructure and healthcare expenditure are the key growth factors in Asia Pacific actinic keratosis market.
Browse the full report Actinic Keratosis: Market Growth, Future Prospects and Competitive Analysis, 2016-2022 report at http://www.credenceresearch.com/report/actinic-keratosis-market
This market is majorly driven by wide presence of generic drugs and is moderately competitive. Photodynamic therapy market has developed a niche with methyl aminolevulinate and aminolevulinic acid drugs. Galderma and DUSA pharmaceuticals are the chief players in this space. Some of the major players in the global actinic keratosis market are Tolmar Pharmaceuticals, Inc, DUSA Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Aqua Pharmaceuticals, LLC, Galderma SA, Perrigo Company plc, LEO Laboratories, Apotex and others.
Kidney Stone Management Devices Market By Treatment Type (Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy (PCNL)) Growth, Share, Opportunities & Competitive Analysis, 2016 -2022
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
What we do
We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.
No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.
Web: Credence Research
Company Name: Credence Research
Contact Person: Chris Smith, Global Sales Manager
Address:105 N 1st ST #429
City: SAN JOSE
Country: United States